SINTX Achieves First Human Implant with FDA-Cleared Foot & Ankle System
Event summary
- Completed first human implant of the FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System on March 13, 2026.
- Appointed Ryan Elmore as President effective March 16, 2026, to lead commercialization efforts.
- Raised approximately $10 million in capital and expanded patent portfolio in 2025.
- Initiated preclinical studies for silicon nitride applications in sutures, meshes, and wound care.
The big picture
SINTX is transitioning from R&D to commercialization, leveraging its silicon nitride platform across multiple medical applications. The appointment of Ryan Elmore signals a focus on scaling revenue through strategic partnerships and market expansion. The global foot and ankle reconstruction market presents a significant opportunity, with SINTX positioning its technology for broader orthopedic adoption.
What we're watching
- Commercial Execution
- How SINTX will scale surgeon adoption and distribution channels for the SINAPTIC system.
- Technology Expansion
- Whether preclinical studies validate silicon nitride's potential in soft tissue applications.
- Strategic Partnerships
- The pace at which SINTX secures collaborations for additive manufacturing and OEM supply.
Related topics